Meeting
2022 ASCO Annual Meeting
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence.
Authors
Elisabeth Livingstone
Department of Dermatology, University Hospital Essen, Essen, Germany
Elisabeth Livingstone , Andrea Forschner , Jessica Cecile Hassel , Lena M. Wulfken , Friedegund Elke Meier , Peter Mohr , Katharina C. Kähler , Bastian Schilling , Carmen Loquai , Carola Berking , Svea Hüning , Julia Eckardt , Ralf Gutzmer , Lydia Reinhardt , Bernd Kowall , Wolfgang Galetzka , Axel Hauschild , Lisa Zimmer , Dirk Schadendorf , Georg Lodde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9570)
DOI
10.1200/JCO.2022.40.16_suppl.9570
Abstract #
9570
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2021 ASCO Annual Meeting
Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.
First Author: B. Adi Kartolo
Poster
2021 ASCO Annual Meeting
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
First Author: Michael B. Atkins
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu